Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arformoterol inhalation solution in COPD (phase 3, China)
CTR20241475Phase 3Completed
- Sponsor
- Hunan Huana Pharmaceuticals
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of arformoterol in chronic obstructive pulmonary disease (COPD), sponsored by Hunan Huana Pharmaceuticals. Started Apr 2024; status: completed.
02
Drugs
arformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20241475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241475.